Hemophilia A Without Inhibitor
8
1
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Treatment Research
11 treatments under study, led by Emicizumab
Research Leaders
18 sponsors active, led by Dutch Society of Haemophilia Patients
Related Conditions
Often studied with 9 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
12.5%
1 terminated out of 8 trials
66.7%
-19.9% vs benchmark
38%
3 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (8)
The Effects of Virtual Reality-Based Gamified Rehabilitation in Children With Hemophilia
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors
Multidimensional Assessment of Chronic Pain in Severe Haemophilia A
Pharmacokinetic-guided Dosing of Emicizumab
The Hemophilia Inhibitor Prevention Trial
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
The Safety of Emicizumab SC Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors
HemFitBit, an Observational Study of Physical Activity in People With Moderate and Severe Haemophilia A
Research Network
Common Treatments
- Emicizumab2
- Homebased Exercise Intervention1
- Kn0571
- Emicizumab Dosis Continuation Group1
- Emicizumab Dose Adjustment Group1
Active Sponsors
- Dutch Society of Haemophilia Patients1
- Amsterdam University Medical Center1
- Oslo University Hospital1
- Leiden University Medical Center1
- Catalyst Biosciences1
Top Investigators
Nanfang Hospital, Southern Medical University
First Affiliated Hospital of Guangxi Medical University
Shengjing Hospital of China University
Jiangxi Provincial People's Hopital
Henan Cancer Hospital
Related Conditions
- Hemophilia A With Inhibitor3
- Hemophilia B Without Inhibitor2
- Hemophilia B1
- Adult1
- Hemophilia B With Inhibitor1